Key result
Understanding the pathophysiology and available treatment options for bioresorbable scaffold failure is essential for ensuring procedural and long-term clinical success in complex coronary lesions.
Understanding the pathophysiology and treatment options for bioresorbable scaffold failure is crucial for ensuring procedural and long-term clinical success in complex CAD lesions.
Supports individualized BRS failure management in complex lesions; leaves open prospective trials to define optimal strategies.
Bioresorbable scaffolds (BRS) are a promising new interventional treatment strategy for coronary artery disease (CAD). They are intended to overcome some of the shortcomings of metal drug-eluting stents (DES), mainly late reinterventions which occur at a consistent rate after one year and have not been reduced by the use of local drug elution. Initial experience in non-complex lesions established efficacy in opening the vessel and the concept of bioresorption. However, with the use of BRS in more complex lesions, the incidence of BRS failure, including both scaffold restenosis and thrombosis, has also increased. Therefore, understanding of both the pathophysiology and of the available treatment options of scaffold failure remains an important issue in ensuring procedural and long-term clinical success.
No takes yet. Share an insight, caveat, or question.
Felix et al. (2015) conducted a review in Coronary artery disease (CAD) / Bioresorbable scaffold failure. Treatment of bioresorbable scaffold failure was evaluated. Understanding the pathophysiology and available treatment options for bioresorbable scaffold failure is essential for ensuring procedural and long-term clinical success in complex coronary lesions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: